Reported 2 months ago
Deutsche Bank has upgraded its rating on Eli Lilly from Hold to Buy, increasing the price target to $1,025 per share. Analyst James Shin attributes this positive outlook to the company's improved visibility and strong demand for its GLP-1 weight-loss drug Mounjaro, which has recently met its sales benchmarks despite ongoing supply challenges. The firm recognizes Eli Lilly's efforts to expand production capabilities as a response to current demand exceeding supply.
Source: YAHOO